Jiangchuan Macrolide Facility Update

July 16, 2010

CHENGDU, China, July 16 /PRNewswire-Asia-FirstCall/ — Tianyin
Pharmaceutical (NYSE Amex: TPI), a pharmaceutical company that specializes in
patented biopharmaceutical, modernized traditional Chinese medicine and
branded generics provides progress update on its Jiangchuan macrolide facility.

The construction of the facility is on schedule, targeting August for
completion and equipment installation, immediately followed by GMP
certification and trial production. The state-of-the-art macrolide facility,
occupying 100mu (~16.5 acres) of land at Sichuan Xinjin Industrial Park near
Chengdu, is designed for a total annual capacity of 240 tons of macrolide
Active Pharmaceutical Ingredients (API) to serve the growing macrolide
antibiotics market.

Jiangchuan macrolide initiative, established in 2009, is designed for the
research and development, manufacturing and sales & marketing of API and
chemical intermediates of macrolide antibiotics for Azithromycin,
Clarithromycin, and Roxithromycin.

Dr. Jiang Guoqing, CEO of Tianyin Pharmaceutical pointed out, “Jiangchuan
macrolide initiative expands our scope of business into the large arena of
antibiotics. Jiangchuan is not only of great strategic significance and
sustainable economic benefits, but also projected to become a leading
manufacturer of macrolide antibiotics in China. It captures the growth
momentum created by the ongoing healthcare reform. The steady increase of the
macrolide raw material prices reaffirmed our market forecast. Additionally,
the API business has an efficient profit chain that consists of three key
elements: 1) raw material processing, 2) API production, and 3) sales, which
are favorable for its healthy cash flow and resilient profit margins.”

About macrolide antibiotics

Macrolide antibiotics prevent the bacterial growth by interfering with
their protein synthesis, through binding to the bacterial ribosomal subunit
50S, thus subsequently inhibiting the translocation of peptides. Among the
commonly used macrolides, azithromycin accounted for more than 50% of the
China’s macrolide market. Azithromycin is an effective and well tolerated in
the treatment of respiratory tract, skin and soft tissue infections in
children. Pathogens susceptible to azithromycin include Haemophilus influenzae
(including ampicillin-resistant strains), Moraxella catarrhalis, Chlamydia
pneumoniae, Chlamydia trachomatis, Mycoplasma pneumoniae, Legionella spp.,
Streptococcus pyogenes and Streptococcus agalactiae. Azithromycin is
administered once daily, achieves clinically relevant concentrations at sites
of infection, and has few drug interactions (Langtry and Balfour Drugs. 1998
Aug 56(2):273-97. Azithromycin. A review of its use in paediatric infectious
diseases). Tianyin’s Azithromycin Dispersible Tablets were included in China’s
essential drug list (EDL), and have enjoyed more than 60% annual revenue
growth since its market debut in 2008.

About Tianyin Pharmaceutical

Tianyin Pharmaceutical Co., Inc., headquartered in Chengdu, Sichuan
of China, is a leading pharmaceutical company that specializes in the
development, manufacturing, marketing and sale of patented medicine,
modernized traditional Chinese medicines and branded generics. Tianyin is
equipped with two state-of- the-art manufacturing facilities and an extensive
nationwide sales and distribution network throughout China. Tianyin currently
manufactures and markets a comprehensive portfolio of 56 products, of which 23
are listed in the highly selective national medical insurance program, 7 are
included in the essential drug list of China. Tianyin has an extensive
nationwide distribution network with a sales force of 720 sales
representatives out of totaled 1,365 employees. Tianyin currently is in the
process of completing its Jiangchuan macrolide facility construction. For more
information about Tianyin, please visit http://www.tianyinpharma.com .

Safe Harbor Statement

The Statements which are not historical facts contained in this press
release are forward-looking statements that involve certain risks and
uncertainties including but not limited to risks associated with the
uncertainty of future financial results, additional financing requirements,
development of new products, government approval processes, the impact of
competitive products or pricing, technological changes, the effect of economic
conditions and other uncertainties detailed in the Company’s filings with the
Securities and Exchange Commission.

    For more information, please contact:

    Tianyin Pharmaceutical Co., Inc.
     James Jiayuan Tong, M.D. Ph.D.
     Chief Financial Officer, Chief Business & Development Officer
     Web:   http://www.tianyinpharma.com
     Email: Dr.Tong@tianyinpharma.com
     Tel:   +86-28-8551-6696 (Chengdu, China)
            +86-134-36-550011 (China)
            +1-949-350-6999 (U.S.)
     Add:   23rd Floor Unionsun Yangkuo Plaza
            No 2 Block 3 South Renmin Road
            Chengdu, 610041

SOURCE Tianyin Pharmaceutical Co., Inc.

Source: newswire

comments powered by Disqus